摘要
目的研究利福喷丁与利福平在肺结核治疗中的药效和安全性。方法选取2017年1月—2018年1月在该院接受治疗的76例肺结核患者为研究对象,按照治疗方法的不同将患者分为两组,研究组和对照组,每组38例。研究组采用利福喷丁治疗,对照组采用利福平治疗。比较两组患者治疗效果病灶吸收情况和不良反应情况。结果研究组治疗总有效率为94.73%,明显高于对照组60.53%的治疗总有效率,差异有统计学意义(χ~2=10.911 3,P<0.05);治疗后,两组患者病灶吸收率之间的差异有统计学意义(χ~2=7.577 3,P<0.05);研究组不良反应率为21.05%,明显低于对照组78.95%的不良反应率,差异有统计学意义(χ~2=23.210 5,P<0.05)。结论利福喷丁应用于肺结核疾病治疗中比利福平具有更好的效果,而且安全性高。
Objective To study the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis. Methods 76 patients with pulmonary tuberculosis who were treated in our hospital from January 2017 to January 2018 were enrolled. The patients were divided into two groups according to different treatment methods. The study group and the control group, 38 cases in each group. The study group was treated with rifapentine and the control group was treated with rifampicin. The absorption and adverse reactions of the treatment effect were compared between the two groups. Results The total effective rate of the study group was 94.73%, which was significantly higher than the total effective rate of 60.53% of the control group, which was statistically significant(χ^2=10.911 3, P<0.05). After treatment, the difference between the two groups was analyzed, statistically significant(χ^2=7.577 3, P<0.05);the adverse reaction rate of the study group was 21.05%, which was significantly lower than the adverse reaction rate of 78.95% in the control group, the difference was statistically significant(χ^2=23.210 5, P<0.05). Conclusion Rifampicin has a better effect and is safer than rifampicin in the treatment of tuberculosis.
作者
杨淑仙
YANG Shu-xian(Beijing Red Cross Emergency Rescue Center, West Station Medical Security Center, Beijing, 100000 China)
出处
《系统医学》
2019年第3期68-70,共3页
Systems Medicine
关键词
利福喷丁
利福平
肺结核
药效
安全性
Rifapentine
Rifampicin
Tuberculosis
Efficacy of drug
Safety
